Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ELOVL1 | Q9BW60 | 10/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.51 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.51 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20968019 | 0.85 | AAK1 (0.49) | MAPTTSHRHTTHSD17B10L3MBTL1 | |
| SCHEMBL20944564 | 0.82 | ELOVL1 (0.54) | MAPTTSHRHTTHSD17B10L3MBTL1 | |
| SCHEMBL20944424 | 0.78 | ELOVL1 (0.52) | MAPTTSHRHTTHSD17B10L3MBTL1 | |
| SCHEMBL19492537 | 0.77 | ELOVL1 (0.46) | MAPTTSHRHTTHSD17B10L3MBTL1 | |
| SCHEMBL20944687 | 0.76 | MAPT (0.55) | MAPTTSHRHTTHSD17B10L3MBTL1 | |
| SCHEMBL10616565 | 0.73 | MAPT (0.50) | MAPTTSHRHTTHSD17B10L3MBTL1 | |
| SCHEMBL19492538 | 0.73 | ELOVL1 (0.44) | MAPTTSHRHTTHSD17B10L3MBTL1 | |
| SCHEMBL20944566 | 0.70 | ELOVL1 (0.52) | MAPTTSHRHTTHSD17B10L3MBTL1 | |
| SCHEMBL20944426 | 0.69 | HTT (0.53) | MAPTTSHRHTTHSD17B10L3MBTL1 | |
| SCHEMBL9646405 | 0.68 | MAPT (0.62) | MAPTTSHRHTTHSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577360-B2 | Arylamide derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-03-03 | — | — | US | disclosed |
| US-20190127357-A1 | ARYLAMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577360-B2 | Arylamide derivatives having multimodal activity against pain | OPRD1, TRPV1, OPRL1 | MAPT 1396/4885TSHR 1967/4885HTT 1680/4885 |
| US-20190127357-A1 | ARYLAMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, TRPV1, OPRL1 | MAPT 1396/4885TSHR 1967/4885HTT 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.